<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167452</url>
  </required_header>
  <id_info>
    <org_study_id>AMA IRB A10-3592</org_study_id>
    <secondary_id>5UL1RR024982-02</secondary_id>
    <nct_id>NCT01167452</nct_id>
  </id_info>
  <brief_title>Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations</brief_title>
  <official_title>Population Pharmacokinetic Analysis of Sulfamethoxazole and Trimethoprim in Normal Weight, Overweight, and Obese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will find how weight affects the dosing of a drug called sulfamethoxazole and
      trimethoprim. Currently, the amount of sulfamethoxazole and trimethoprim a patient receives
      is the same regardless of the patient's weight. The entire cohort was analyzed for the study
      outcomes. BMI groups were for recruitment purposes only and were not used for ordinal data
      analysis.

      All sulfamethoxazole and trimethoprim (Trade name is Bactrim or Septra) medication that you
      will receive in this study will be referred to as study medication within this informed
      consent form. This drug is a combination of two antibiotics, sulfamethoxazole and
      trimethoprim, which belongs to a class of medication known as &quot;sulfones&quot; and is approved by
      the US Food and Drug Administration (FDA) for the treatment of a wide variety of bacterial
      infections such as ear infections, urinary tract infections, bronchitis, traveler's diarrhea,
      and Pneumocystis carinii pneumonia. Sulfamethoxazole and trimethoprim is given orally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to measure drug concentrations in the blood of volunteers administered
      a single oral dose of sulfamethoxazole and trimethoprim. The volunteers to be enrolled will
      not have ear infections, urinary tract infections, bronchitis, traveler's diarrhea,
      Pneumocystis carinii pneumonia, or any other bacterial infection. This is a single center
      study. A total of 36 adult volunteers will be consented for the study at the Clinical and
      Translational Research Center (CTRC). Volunteers will be recruited using IRB approved fliers.
      Volunteers will be admitted to the CTRC for an overnight stay. Half will be female and half
      male. Twelve volunteers will have a body mass index (BMI) less than 25 kg/m2, twelve will
      have a BMI 25-40 kg/m2, and twelve will have a BMI greater than 40 kg/m2. Volunteers will
      have height and weight measured after they have consented to participate. All volunteers will
      receive a single oral dose of sulfamethoxazole and trimethoprim of 1600 mg/320 mg. The
      volunteers will have blood drawn via an intravenous catheter just prior to the dose, and then
      at 1, 2, 4, 8, 12, and 24h after the drug dose. The intravenous catheter is then removed
      after the 24h blood draw, and the volunteer is discharged from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elimination Rate Constants for Sulfamethoxazole and Trimethoprim</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Obesity</condition>
  <condition>Pharmacokinetics</condition>
  <condition>MRSA</condition>
  <condition>Tuberculosis</condition>
  <condition>PCP</condition>
  <arm_group>
    <arm_group_label>Sulfamethoxazole/trimethoprim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole/trimethoprim</intervention_name>
    <description>2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose</description>
    <arm_group_label>Sulfamethoxazole/trimethoprim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, age &gt;18 years, of all racial and ethnic origins.

          -  We are recruiting 12 normal or underweight (BMI &lt;25kg/m2), 12 overweight or obese (BMI
             25-40 kg/m2), and 12 extremely obese (BMI &gt; 40 kg/m2) for this study. This index is
             calculated using the volunteer's height and weight (Formula: weight (lb) / [height
             (in)]2 x 703). Half of each group will be male; the other half will be female.

        Exclusion Criteria:

          -  Pregnant or nursing or unwilling to use a reliable contraception method during the
             study. The effects of sulfamethoxazole and trimethoprim on pregnancy are unknown. In
             addition, the metabolic changes that accompany pregnancy may alter the
             concentration-time profile of sulfamethoxazole and trimethoprim, so that the pregnancy
             and post-partum state would be a confounding variable.

          -  Abnormal liver function tests: transaminases&gt;10 times upper limit of normal, Alkaline
             phosphatase&gt;5 times upper limit of normal, total bilirubin&gt;5 times upper limit of
             normal.

          -  History of allergies to sulfones, sulfonamides or trimethoprim.

          -  Sulfones, sulfonamides or trimethoprim are contraindicated for any reason.

          -  Volunteers unwilling to comply with study procedures.

          -  Current suspected or documented ear infection, urinary tract infection, bronchitis,
             traveler's diarrhea, Pneumocystis carinii pneumonia, or any other bacterial infection.

          -  Volunteers with colon resection, gastric bypass, lap band, or any other conditions
             inhibiting gastric absorption of drug.

          -  Current or previous participation within 28 days of enrollment in another research
             study that involves the use of medication, contrast, or any other compound that may
             alter blood count and/or blood chemistry (liver function, kidney function or
             electrolyte balance), unless waved by PI.

          -  Donation of 450mL (one unit) of blood or more within 8 weeks (56 days) prior to study
             enrollment, unless waved by PI.

          -  Current use of medications contraindication with sulfamethoxazole/trimethoprim use:
             Bepridil, Cisapride, Dofetilide, Levomethadyl, Mesoridazine, Pimozide, Terfenadine,
             and Thioridazine. Other medications will be screened by study investigators to ensure
             the safety of research participants and maintain the quality of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Hall, PharmD, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech UHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1002/psp4.12146/full</url>
    <description>Link to manuscript describing our findings</description>
  </link>
  <results_reference>
    <citation>Hall RG Nd, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T. Fractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People. CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):674-681. doi: 10.1002/psp4.12146. Epub 2016 Nov 21.</citation>
    <PMID>27869362</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <results_first_submitted>August 16, 2016</results_first_submitted>
  <results_first_submitted_qc>October 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 2, 2016</results_first_posted>
  <disposition_first_submitted>February 4, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 22, 2014</disposition_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University Health Sciences Center</investigator_affiliation>
    <investigator_full_name>Ron Hall</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>MRSA</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>PCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulfamethoxazole/Trimethoprim</title>
          <description>2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
Sulfamethoxazole/trimethoprim: 2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulfamethoxazole/Trimethoprim</title>
          <description>All volunteers received a single dose oral dose of TMP/SMX (1600 mg/320 mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="18" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Elimination Rate Constants for Sulfamethoxazole and Trimethoprim</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulfamethoxazole</title>
            <description>Results from sulfamethoxazole analysis</description>
          </group>
          <group group_id="O2">
            <title>Trimethoprim</title>
            <description>Results from trimethoprim analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constants for Sulfamethoxazole and Trimethoprim</title>
          <units>hr-1</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" lower_limit="0.015" upper_limit="0.180"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.02" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>We conducted a linear regression analysis of the log transformed elimination rate constant vs. the log transformed weight for each participant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Regression, Linear</method>
            <method_desc>Multivariate adaptive regression spline (MARS) analysis</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We conducted a linear regression analysis of the log transformed elimination rate constant vs. the log transformed body mass index for each participant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <method_desc>Multiple Adaptive Regression Spline (MARS)</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulfamethoxazole/Trimethoprim</title>
          <description>All volunteers received a single dose of TMP/SMX (1600 mg/320 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Mild headache post-dose (possibly related)
One person with a headache also had elevated blood pressure, skin irritation under the medical dressing over the IV line insertion site, and a mild rash (neck, ears); all deemed not related to study drug.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fainting</sub_title>
                <description>One person fainted during the screening blood draw, which we judged not to be related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Hall, PharmD, MSCS</name_or_title>
      <organization>Texas Tech University Health Sciences Center</organization>
      <phone>214-358-9009</phone>
      <email>ronald.hall@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

